Critical Pharmaceuticals and The University of Nottingham to Develop Nano-Enabled Nasal Spray for Osteoporosis
News Feb 16, 2012
Critical Pharmaceuticals, an emerging biotechnology company, and The University of Nottingham today announce a £545,000 collaboration to develop a nano-enabled intranasal formulation of teriparatide for the treatment of osteoporosis. Osteoporosis affects an estimated 75 million people in Europe, US and Japan with more than 180,000 patients suffer fragility fractures in the UK alone each year, at a cost of around £2 billion to the NHS.
Teriparatide, an excellent recent addition to the range of drugs used for the treatment of osteoporosis, but it currently needs to be injected every day. Our consortium will exploit a recent discovery in nanotechnology to develop a nasal spray formulation of teriparatide that is easy to administer by patients and provides optimal drug plasma levels to enhance efficacy.
The Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC) are supporting this project with grant funding as part of their investment in nanoscale technology-enabled solutions in healthcare.
Critical Pharmaceuticals CriticalSorb™ nanotechnology is a best in class absorption promoter that enables the nasal delivery of biological and challenging small molecule drugs. Biological drugs represent a $100 billion market, and yet nearly all need to be administered by frequent injection. CriticalSorb™ has the potential to transform the delivery of biological drugs by enabling non-invasive delivery that would be strongly preferred by patients. Critical Pharmaceuticals lead product is a nasal formulation of human growth hormone (CP024) that uses CriticalSorb™ and is currently in phase 1 clinical development.
Dr Gareth King, CEO Critical Pharmaceuticals said “We are excited about working with internationally-recognized clinicians and scientists at The University of Nottingham and Nottingham University Hospitals NHS Trust to rapidly develop this highly innovative formulation of teriparatide and look forward to the day we can offer it as an attractive alternative to daily injection for the many older people living with osteoporosis”.
The University of Nottingham has world-leading capabilities in clinical and basic research in osteoporosis, geriatric care, bone pathophysiology and medical imaging. The use of university expertise for imaging drug deposition and clearance will greatly enhance the development of this formulation. This project will draw on interdisciplinary collaborative research from international experts Dr Richard Pearson (Division of Orthopaedic & Accident Surgery), Professor Alan Perkins (Division of Radiological and Imaging Sciences) and Professor Tahir Masud (Geriatric Medicine).
Dr Richard Pearson, Senior Research Fellow in The University of Nottingham’s Faculty of Medicine and Health Sciences, said “I’m delighted to collaborate on this project that will enable us to further develop the world-leading research and development capability at the University of Nottingham for the evaluation of drugs for osteoporosis and to work closely with Critical Pharmaceuticals scientists on the development of an exciting new therapy for this debilitating disease”.
When people take MDMA, the drug popularly known as ecstasy, a rush of serotonin, dopamine, and oxytocin makes people more interested than they would normally be in connecting and sharing with other people. Now, researchers have made the surprising discovery that a species of octopus considered to be asocial responds to MDMA in the same way.